BeiGene to Approve and Publish Annual Results in Hong Kong

An update from BeiGene Ltd ( (HK:6160) ) is now available.

BeiGene, Ltd. announced that its audit committee will meet on March 27, 2025, to approve and publish the company’s annual results for the year ended December 31, 2024, in accordance with the Hong Kong Listing Rules. This announcement aligns with the company’s previous filing of its annual results with the U.S. SEC, ensuring compliance with both U.S. and Hong Kong financial reporting standards, which may impact stakeholders by providing transparency and consistency in financial disclosures.

More about BeiGene Ltd

BeiGene, Ltd. is a biotechnology company incorporated in the Cayman Islands, focusing on the development and commercialization of innovative cancer treatments. It operates in the pharmaceutical industry with a market focus on oncology therapies.

YTD Price Performance: 36.81%

Average Trading Volume: 3,134,660

Technical Sentiment Consensus Rating: Strong Sell

Current Market Cap: HK$214.6B

For a thorough assessment of 6160 stock, go to TipRanks’ Stock Analysis page.